Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fexuprazan + aspirin
- Development stage
- Phase 1
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWP14012 + DWC202005 is an investigational combination drug product being developed by Daewoong Pharmaceutical for the treatment of gastroesophageal reflux disease (GERD) and the prevention of gastric damage in patients requiring antiplatelet therapy. The combination consists of fexuprazan (DWP14012), a potassium-competitive acid blocker (P-CAB), and aspirin (DWC202005), a salicylate that acts as an antiplatelet agent and nonsteroidal anti-inflammatory drug (NSAID). Fexuprazan provides rapid and reversible inhibition of the gastric H+/K+-ATPase (proton pump), effectively suppressing acid secretion. Aspirin acts by irreversibly inhibiting cyclooxygenase enzymes, primarily COX-1, to prevent platelet aggregation. This combination is primarily evaluated in pharmacokinetic interaction studies to ensure that the acid-suppressing effects of fexuprazan do not interfere with the absorption or efficacy of aspirin, particularly enteric-coated formulations.
- Other names
- fexuprazan + aspirinabeprazan + aspirinDWP14012 + DWC202005
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on fexuprazan + aspirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fexuprazan + aspirin.